C-4' modified adenosine kinase inhibitors

Details C-4' modified adenosine kinase inhibitors C-4' modified adenosine kinase inhibitors

1995-06-07

1997-10-07

Wilson, James O.

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

536 272, 536 2721, 536 2723, 536 2762, 544254, 544262, 544264, 544265, 544266, 544267, 544271, 544272, 544273, 544277, 544280, C07H 19044, C07H 1914

Patent

active

056749988

ABSTRACT:
This invention relates to adenosine kinase inhibitors and to nucleoside kinase inhibitors. The invention relates to nucleoside analogs of this kind, having zero substitutions or two substitutions at the C-4' position of the furanose (sugar) moiety. The invention also relates to the preparation and use of these adenosine kinase inhibitors in the treatment of cardiovascular, and cerebrovascular diseases, inflammation and other diseases which can be regulated by increasing the local concentration of adenosine.

REFERENCES:
patent: 4455420 (1984-06-01), Kazlauskas
patent: 4904666 (1990-02-01), Friebe
patent: 5506347 (1996-04-01), Erion et al.
Achterberg et al., Biochem. J., 235, 13-17 (1986).
Barker, R. et al., J. Org. Chem., 26: 4605 (1961).
Barton, D. H. et al., Pure Appl. Chem. 53:15 (1981).
Bontemps et al., Proc. Natl. Acad. Sci. USA, 80, 2829-33 (1983).
Burke et al., J. Neurochem, 51: 1541 (1988).
Berkowitz, W. F. et al., J. Org. Chem. 52:1119 (1987).
Caldwell and Henderson, Cancer Chemother. Rep., 2, 237-46 (1971).
Cheng, C.C. J. Org. Chem. 21:1240 (1956).
Cossy J. et al., Tet Lett 28: 4547 (1987).
Cottam, H.B., et al., J. Med. Chem., 27, 119-27 (1984).
Davies et al., Biochem. Pharmacol., 35, 3021-29 (1986).
Davies et al., Biochem. Pharmacol., 33, 347-55 (1984).
Fetizon, M. et al., Chem. Soc. Chem Comm. 382 (1972).
Firestein et al., J. Immunology 154, 326-34 (1995).
Gewald, R., Z. Chem. 1, 349 (1961).
Green, J. Supramol. Structure, 13:175-182 (1980).
Henderson et al., Cancer Chemotherapy Rep. Part 2, 3, 71-85 (1972).
Inokawa, S. et al., Carbohydrate Res. 30: 127 (1973).
Jefford, C.W. et al., JACS 94: 8905 (1972).
Johnson, C.R. et al., J. Org. Chem. 59: 5854 (1994).
Juaristi, E. et al., Tet Lett 25:3521 (1984).
Keil et al., Life Sciences 5, 171-76 (1992).
Kobayashi, S., Chem. Pharm. Bull., 21, 941-51 (1973).
Koll P. et al., Ang. Chem. Int. Ed. Eng., 25: 368 (1986).
Leonard, N.J. et al., J. Heterocyclic Chem. 3: 485 (1966).
Newby et al., Biochem. J., 214, 317-323 (1983).
Miller et al., J. Biol. Chem., 254, 2346-52 (1979).
Molander, G.A. et al., JACS 109: 453 (1987).
Mori, K. et al., Tetrahedron 43: 2229 (1987).
Pak et al., Soc. for Neuroscience Abs., 20, 149.2 (1994).
Paquette, L.A. et al., JACS 108: 3841 (1986).
Pecquet, P. et al., Heterocycles 34: 739 (1992).
Phillis et al., Life Sciences, 53, 497-502 (1993).
Prescott et al., Nucleosides & Nucleotide, 8, 297 (1989).
Redlich, H. Angew. Chem. 101: 764 (1989).
Romming, C. et al., Act. Chem. Scan. B. 40: 434 (1986).
Rosemeyer, H. and Seela, F., Helv. Chim. Acta, 71, 1573-85 (1988).
Samano, V. et al., Tet Lett. 35: 3445 (1994).
Schrader, in Regulatory Function of Adenosine; Berne et al., eds. pp. 133-156 (1983).
Sciotti et al., J. Cerebral Blood Flow Metab., 13, 201-207 (1993).
Simmons, H.E. et al., JACS 81: 4256 (1959).
Snyder, J.R. et al., Carbohydrate Res., 163, 169-88 (1987).
Srivastava, P.C. et al., J. Med. Chem. 18:1237 (1975).
Taylor, E.C. and Hendess, R.W. J. Am. chem. Soc., 87, 1995-2003 (1965).
Tufariello, J. et al. Tet Lett 6145 1966).
van der Does, J. Tet Lett 27:519 (1986).
Vaughan W.R. et al., J. Org. Chem. 26: 138 (1961).
Von E. Doering et al., JACS 76, 6162 (1954).
White, Soc. Neurosci. Abs., 20, 308.9 (1994).
Wu, et al., Cytobios, 50, 7-12 (1987).
Youssefyeh, R. P. et al., J. Org. Chem. 44: 1301 (1979).
Zhang et al., J. Pharmacol. Exper. Ther. 264(3), 1415 (1993).
Zoref-Shani et al., J. Mol. Cell. Cardiol., 20, 23-33 (1988).

Affiliated with

Also associated with

Rating

C-4' modified adenosine kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with C-4' modified adenosine kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and C-4' modified adenosine kinase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2358333